🇺🇸 FDA
Patent

US 7132392

Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain

granted A61KA61K38/05A61K38/06

Quick answer

US patent 7132392 (Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Nov 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Nov 07 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K38/05, A61K38/06, A61K38/07, A61P